<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34905446</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>02</Day></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Immunogenicity and safety of an inactivated enterovirus 71 vaccine co-administered with measles-mumps-rubella vaccine and live-attenuated Japanese encephalitis vaccine: a phase 4, single-center, randomized controlled trial.</ArticleTitle><Pagination><StartPage>5348</StartPage><EndPage>5354</EndPage><MedlinePgn>5348-5354</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2021.2010428</ELocationID><Abstract><AbstractText>Co-administration of vaccines could be an efficient strategy to increase vaccination uptake and reduce the number of clinic visits. This randomized controlled study aimed to evaluate the immunogenicity and safety of enterovirus 71 (EV71) vaccine co-administered with measles-mumps-rubella (MMR) vaccine and live-attenuated Japanese encephalitis vaccine (LA-JEV). A total of 372 healthy infants were randomly assigned in a 1:1:1 ratio to receive simultaneous administration of EV71 vaccine (dose 1) and MMR on d 0 and EV71 vaccine (dose 2) and LA-JEV on d 30 (Group 1); administration of MMR and LA-JEV on d 0 and 30, respectively (Group 2); or administration of doses 1 and 2 of EV71 vaccine on d 0 and 30, respectively (Group 3). The non-inferiority analysis of the seroconversion for EV71 neutralizing antibody after vaccination was the primary outcome. According to per protocol set, antibody response against EV71, measles, mumps, rubella, and Japanese encephalitis (JE) virus was similar regardless of administration schedule. After vaccination, the seroconversion rate of EV71 neutralizing antibody in Group 1 (107 [97.27%] of 110) was non-inferior to that in Group 3 (109 [97.32%] of 112; difference - 0.05% [95% CI - 5.38 to 5.21]). The incidences of adverse reactions were 62.60% (77/123) in Group 1, 54.84% (68/124) in Group 2, and 37.70% (46/122) in Group 3, and most of them were mild to moderate in severity. No vaccine-related serious adverse events were reported. In total, the co-administration of combined EV71 vaccine with MMR and LA-JEV showed no interference with antibody response and demonstrated good safety profiles.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiaoyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Center for Clinical Evaluation of Vaccines, Shaanxi Provincial Center for Disease Control and Prevention, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Wanqi</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Sinovac Biotech Co. Ltd, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Clinical Evaluation of Vaccines, Shaanxi Provincial Center for Disease Control and Prevention, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Heng</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Immunology, Hanbin District Center for Disease Control and Prevention, Ankang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ruize</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center for Clinical Evaluation of Vaccines, Shaanxi Provincial Center for Disease Control and Prevention, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Immunology, Hanbin District Center for Disease Control and Prevention, Ankang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Immunology, Hanbin District Center for Disease Control and Prevention, Ankang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Yongli</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Sinovac Biotech Co. Ltd, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Shaobai</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Clinical Evaluation of Vaccines, Shaanxi Provincial Center for Disease Control and Prevention, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lin</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-2571-4320</Identifier><AffiliationInfo><Affiliation>Sinovac Biotech Co. Ltd, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017429">Clinical Trial, Phase IV</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022321">Japanese Encephalitis Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022542">Measles-Mumps-Rubella Vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017778">Vaccines, Combined</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004664" MajorTopicYN="Y">Encephalitis Virus, Japanese</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D022321" MajorTopicYN="Y">Japanese Encephalitis Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008457" MajorTopicYN="Y">Measles</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022542" MajorTopicYN="N">Measles-Mumps-Rubella Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009107" MajorTopicYN="Y">Mumps</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012409" MajorTopicYN="Y">Rubella</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017778" MajorTopicYN="N">Vaccines, Combined</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Co-administration</Keyword><Keyword MajorTopicYN="N">EV71 vaccine</Keyword><Keyword MajorTopicYN="N">immunogenicity</Keyword><Keyword MajorTopicYN="N">live-attenuated Japanese encephalitis vaccine</Keyword><Keyword MajorTopicYN="N">measles-mumps-rubella vaccine</Keyword><Keyword MajorTopicYN="N">safety</Keyword></KeywordList><CoiStatement>WY, YX, and LW are employees of Sinovac Biotech Co., Ltd. All other authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>14</Day><Hour>17</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34905446</ArticleId><ArticleId IdType="pmc">PMC8903949</ArticleId><ArticleId IdType="doi">10.1080/21645515.2021.2010428</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T.. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 2010;9(11):1097&#x2013;105. doi:10.1016/S1474-4422(10)70209-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70209-X</ArticleId><ArticleId IdType="pubmed">20965438</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang PC, Chen SC, Chen KT.. The current status of the disease caused by enterovirus 71 infections: epidemiology, pathogenesis, molecular epidemiology, and vaccine development. Int J Environ Res Public Health. 2016;13(9). doi:10.3390/ijerph13090890.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph13090890</ArticleId><ArticleId IdType="pmc">PMC5036723</ArticleId><ArticleId IdType="pubmed">27618078</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt NJ, Lennette EH, Ho HH. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis. 1974;129(3):304&#x2013;09. doi:10.1093/infdis/129.3.304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/129.3.304</ArticleId><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>Lum LC, Wong KT, Lam SK, Chua KB, Goh AY. Neurogenic pulmonary oedema and enterovirus 71 encephalomyelitis. Lancet. 1998;352(9137):1391. doi:10.1016/s0140-6736(05)60789-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(05)60789-1</ArticleId><ArticleId IdType="pubmed">9802304</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun LM, Zheng HY, Zheng HZ, Guo X, He JF, Guan DW, Kang M, Liu Z, Ke CW, Li JS, et al. An enterovirus 71 epidemic in Guangdong Province of China, 2008: epidemiological, clinical, and virogenic manifestations. Jpn J Infect Dis. 2011;64(1):13&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">21266750</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010;10(11):778&#x2013;90. doi:10.1016/S1473-3099(10)70194-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito S, Principi N. Hand, foot and mouth disease: current knowledge on clinical manifestations, epidemiology, aetiology and prevention. Eur J Clin Microbiol Infect Dis. 2018;37(3):391&#x2013;98. doi:10.1007/s10096-018-3206-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-018-3206-x</ArticleId><ArticleId IdType="pubmed">29411190</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh WM, Bogich T, Siegel K, Jin J, Chong EY, Tan CY, Chen MI, Horby P, Cook AR. The epidemiology of hand, foot and mouth disease in Asia: a systematic review and analysis. Pediatr Infect Dis J. 2016;35(10):e285&#x2013;e300. doi:10.1097/INF.0000000000001242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000001242</ArticleId><ArticleId IdType="pmc">PMC5130063</ArticleId><ArticleId IdType="pubmed">27273688</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J. Trend of epidemics and variation of pathogens of hand, foot and mouth disease in China: a dynamic series analysis, 2008-2017. Chin J Epidemiol. 2019;40(2):147&#x2013;54. doi:10.3760/cma.j.0254-6450.2019.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.0254-6450.2019.02.005</ArticleId><ArticleId IdType="pubmed">30744263</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu W, Zeng G, Hu YM, Hu YS, Zhang Y, Hu YL, Wang Y, Li JX, Zhu FC. A comparative analysis of immunogenicity and safety of an enterovirus 71 vaccine between children aged 3-5 years and infants aged 6-35 months. Expert Rev Vaccines. 2018;17(3):257&#x2013;62. doi:10.1080/14760584.2018.1430572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2018.1430572</ArticleId><ArticleId IdType="pubmed">29363365</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang XF, Lu J, Liu XX, Dai T. Epidemiological features of hand, foot and mouth disease outbreaks among Chinese preschool children: a meta-analysis. Iran J Public Health. 2018;47:1234&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6174039</ArticleId><ArticleId IdType="pubmed">30319997</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng YM, Jit M, Wu JT, Yang J, Leung K, Liao QH, Yu HJ. Economic costs and health-related quality of life for hand, foot and mouth disease (HFMD) patients in China. PLoS One. 2017;12(9):e0184266. doi:10.1371/journal.pone.0184266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0184266</ArticleId><ArticleId IdType="pmc">PMC5608208</ArticleId><ArticleId IdType="pubmed">28934232</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, Tseng FC, Wang JR, Chi CY, Chong P, Su IJ. Challenges to licensure of enterovirus 71 vaccines. PLoS Negl Trop Dis. 2012;6(8):e1737. doi:10.1371/journal.pntd.0001737.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0001737</ArticleId><ArticleId IdType="pmc">PMC3429393</ArticleId><ArticleId IdType="pubmed">22953003</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi EJ, Shin YJ, Kim JH, Kim TG, Chang SY. Enterovirus 71 infection and vaccines. Clin Exp Vaccine Res. 2017;6(1). doi:10.7774/cevr.2017.6.1.4.</Citation><ArticleIdList><ArticleId IdType="doi">10.7774/cevr.2017.6.1.4</ArticleId><ArticleId IdType="pmc">PMC5292356</ArticleId><ArticleId IdType="pubmed">28168168</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Xu WB, Xia JL, Liang ZL, Liu Y, Zhang XF, Tan XJ, Wang L, Mao QY, Wu YM, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370(9):818&#x2013;28. doi:10.1056/NEJMoa1304923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304923</ArticleId><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YP, Liang ZL, Xia JL, Wu JY, Wang L, Song LF, Mao QY, Wen SQ, Huang RG, Hu YS, et al. Immunogenicity, safety, and immune persistence of a novel inactivated human enterovirus 71 vaccine: a phase II, randomized, double-blind, placebo-controlled trial. J Infect Dis. 2014;209(1):46&#x2013;55. doi:10.1093/infdis/jit429.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jit429</ArticleId><ArticleId IdType="pubmed">23922377</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JX, Song YF, Wang L, Zhang XF, Hu YS, Hu YM, Xia JL, Li J, Zhu FC. Two-year efficacy and immunogenicity of Sinovac enterovirus 71 vaccine against hand, foot and mouth disease in children. Expert Rev Vaccines. 2016;15(1):129&#x2013;37. doi:10.1586/14760584.2016.1096782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2016.1096782</ArticleId><ArticleId IdType="pubmed">26460695</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B, Wu P, Wu JT, Lau EHY, Leung GM, Yu H, Cowling BJ. Seroprevalence of enterovirus 71 antibody among children in China: a systematic review and meta-analysis. Pediatr Infect Dis J. 2015;34(12):1399&#x2013;406. doi:10.1097/INF.0000000000000900.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000000900</ArticleId><ArticleId IdType="pmc">PMC4718881</ArticleId><ArticleId IdType="pubmed">26368058</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinese Center for Disease Control and Prevention (CDC) . Technical guidelines for the use of inactivated enterovirus 71 vaccines. Beijing,China: Immunization planning center; 2016. 
June
6 [accessed 2021 Sept
20]. https://www.chinacdc.cn/zxdt/201606/t20160608_131032.html.</Citation></Reference><Reference><Citation>Zhang ZW, Liang ZL, Zeng J, Zhang JK, He P, Su JL, Zeng YM, Fan RF, Zhao D, Ma WJ, et al. Immunogenicity and safety of an inactivated enterovirus 71 vaccine administered simultaneously with hepatitis B vaccine and group a meningococcal polysaccharide vaccine: a phase 4, open-label, single-center, randomized, noninferiority trial. J Infect Dis. 2019;220(3):392&#x2013;99. doi:10.1093/infdis/jiz129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiz129</ArticleId><ArticleId IdType="pubmed">30891604</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang XM. A review of combined immunization: current research situation and its promising future. Chin J Epidemiol. 2020;41(1):120&#x2013;26. doi:10.3760/cma.j.0254-6450.2020.01.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.0254-6450.2020.01.022</ArticleId><ArticleId IdType="pubmed">32062954</ArticleId></ArticleIdList></Reference><Reference><Citation>Stucke K, Kieser M. A general approach for sample size calculation for the three-arm &#x2018;gold standard&#x2019; non-inferiority design. Stat Med. 2012;31(28):3579&#x2013;96. doi:10.1002/sim.5461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.5461</ArticleId><ArticleId IdType="pubmed">22764073</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu YM, Wang X, Wang JZ, Wang L, Zhang YJ, Chang L, Liang ZL, Xia JL, Dai QG, Hu YL, et al. Immunogenicity, safety, and lot consistency of a novel inactivated enterovirus 71 vaccine in Chinese children aged 6 to 59 months. Clin Vaccine Immunol. 2013;20(12):1805&#x2013;11. doi:10.1128/CVI.00491-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00491-13</ArticleId><ArticleId IdType="pmc">PMC3889509</ArticleId><ArticleId IdType="pubmed">24108780</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu Y, Lu YZ, Tao H, Wang B, Wang Y, Wang SQ, Qin J, Xu WQ. Safety and immunogenicity of domestic combined live attenuated measles, mumps and rubella vaccine. Chin J Biol. 2011;24(6):707&#x2013;10. doi:10.13200/j.cjb.2011.06.88.chuy.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.13200/j.cjb.2011.06.88.chuy.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu HJ, Li W, Xia JH, Tao H, Fang HH, Li YJ, Chu Y, Ma FB, Xu WQ, Wang SQ. Adverse reaction and immunogenicity induced by domestic freeze-dried live attenuated measles-mumps-rubella combined vaccine. Chin J Biol. 2008;21(12):1111&#x2013;14. doi:10.13200/j.cjb.2008.12.84.xuhj.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.13200/j.cjb.2008.12.84.xuhj.011</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>